What's Happening?
Countable Labs and Promega have announced a co-marketing agreement to enhance biological sample preparation and rare variant detection. This partnership combines Promega's Maxwell® System for nucleic acid extraction with Countable Labs' Countable PCR
technology. The collaboration aims to provide a comprehensive solution for DNA and RNA quantification, offering high-quality nucleic acids for various applications. The Promega Maxwell® System is known for its efficient nucleic acid extraction, while Countable PCR technology allows for precise single-molecule quantification. This joint offering is designed to improve the detection of rare targets in research and diagnostics, particularly in fields like oncology and molecular diagnostics. The companies plan to host a webinar to discuss the workflow and its applications in liquid biopsy.
Why It's Important?
This partnership is significant for the life sciences industry, as it addresses the need for more accurate and efficient biological sample processing. By combining their technologies, Countable Labs and Promega aim to enhance the precision of rare variant detection, which is crucial for advancements in precision medicine and diagnostics. This collaboration could lead to improved outcomes in research areas such as cancer detection and treatment, where identifying rare genetic variants is essential. The integration of these technologies may also streamline laboratory workflows, reducing time and costs associated with sample processing. This development highlights the ongoing innovation in the life sciences sector, with potential benefits for researchers, clinicians, and patients.
What's Next?
The companies are set to host a joint webinar on July 9, 2026, to provide more information about their integrated workflow for liquid biopsy applications. This event will offer insights into the practical applications of their combined technologies and how they can be utilized in various research and diagnostic settings. Stakeholders in the life sciences industry, including researchers and clinicians, are likely to follow this development closely, as it may influence future practices in sample processing and rare variant detection. The success of this partnership could lead to further collaborations and innovations in the field, potentially expanding the capabilities of precision medicine.
